NASDAQ NMS - GLOBAL MARKET · ARTV
-5.91% · -$0.4300 · Vol 324.6K
Market closed · last close 4:00 PM ET · price as of 16:41:06 ET
Artiva Biotherapeutics Inc

Artiva Biotherapeutics Inc

Biotechnology
$6.84
Card
Relationship Map

Follow $ARTV

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $ARTV by email

Veridion Score

BETALOW CONF · 5 of 6 factors measuredMethodology
Sentiment absence reason unknown
ARTV
Artiva Biotherapeutics Inc
Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

53/ 100
Veridion Score
Middle range · LOW confidence · 5 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: LOW · 5 of 6 factors measured · Wed Oct 7 · last completed session · Markets closed · resumes Thu 9:30 ET
Share on X →
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is ARTV moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading ARTV catalysts
About Artiva Biotherapeutics Inc
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed since
2024
Employees
115
Country
US

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Company website →
Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$7.10
Day high
$7.27
Day low
$6.84
Previous close
$7.27
52W high
$13.39
-48.92% from high
52W low
$2.74
38% of range
Market cap
$355.4M
EPS
$-3.4308
Beta
1.15
Shares out
48.9M
Volume
324.6K
0.72× rel vol
Avg volume
451.7K
VWAP
$7.07
Price history computed in-house
1W
+0.74%
1M
-37.13%
3M
-29.05%
1Y
+128.00%
YTD
+59.44%
SMA 50 $9.94 · below
SMA 200 $7.91 · below
52W position 38%

ARTV overview

Veridion Score
53
Registered · 2026-10-07
5 of 6 factors measured
Latest receipt rows
0
No recent disclosure on file.
13F holders
None on file

Related filings and maps

Relationship mapTrace receipt-backed holders and filings around ARTV.Congress trackerSearch the public STOCK Act disclosure ledger.MethodologyReview score inputs, coverage rules, and limitations.
Loading financial statements
Loading ARTV Form 4 filings
Public disclosures

Congress activity in ARTV

Congress trackerOpen ticker disclosure ledger →

No receipt-qualified filings found.

Federal contracts

ARTV contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for ARTV in this window.
Lobbying spend

ARTV lobbying filings, year to date.

Registered lobbying filings matched to Artiva Biotherapeutics Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for ARTV in this window.
Loading news for ARTV
Analyst ratings
Sovereign unlock shows live analyst consensus for ARTV.
Options
Options data is temporarily unavailable. Changing your plan will not restore the upstream feed.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.